US Pharm. 2010;35(8):58.
For the first time, the Access to Medicine Index has given generic drug makers a separate ranking on its biannual index, and Ranbaxy Laboratories Ltd. and Cipla, both based in India, top the list. “The Access to Medicine Index independently assesses how individual pharmaceutical companies perform in promoting universal access to essential medicines, and is thus an important tool in improving performance,” said Carissa Etienne, MD, assistant director-general at the World Health Organization. Manufacturers were rated on seven factors, including access to medicine management, public policy and market influence, and product donations and philanthropy. The index was first published in 2008 by the Netherlands-based nonprofit Access to Medicine Foundation. Other generic manufacturers included in the 2010 index are Dr. Reddy's Laboratories Ltd., Mylan Inc., Sun Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd.
